Last reviewed · How we verify
IBB0979
At a glance
| Generic name | IBB0979 |
|---|---|
| Sponsor | SUNHO（China）BioPharmaceutical CO., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer (PHASE2)
- A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBB0979 CI brief — competitive landscape report
- IBB0979 updates RSS · CI watch RSS
- SUNHO（China）BioPharmaceutical CO., Ltd. portfolio CI